X4 Pharmaceuticals, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
96.1M
on 2026-06-30, from 5.60M on 2024-03-31 10-Q ↗
Earlier counts are adjusted for the 1-for-30 reverse split; each bar's tip shows the count as filed.
Newest
$300.0M
S-3 of 2026-05-06. Sales under the at-the-market programme filed with it are not stated apart. S-3 ↗
$75.0M
Jefferies, agreement of 2026-05-06. No at-the-market sales statement read from a 10-Q or 10-K. S-3 ↗
Warrants
37.92M
Warrants of every class as tagged in the XBRL facts on 2025-12-31, exercise price $0.03. 10-K ↗
Cash
9.3 quarters
$195.1M on 2026-06-30 ÷ $20.9M a quarter of operating cash used, the average of four quarters. 10-Q ↗
Raised: 13 of its filings are not read yet.